Template:ID-TdP: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) Created page with "* Risk categories for antimicrobial agents known to have an association with TdP :* '''Drugs with known TdP risk''' ::* Azithromycin (Zithromax®, Zmax®) ::*..." |
Gerald Chi- (talk | contribs) mNo edit summary |
||
Line 1: | Line 1: | ||
===Risk categories for antimicrobial agents known to have an association with TdP {{ID-returntotop}}=== | |||
* '''Drugs with known TdP risk''' | |||
:* [[Azithromycin|Azithromycin (Zithromax®, Zmax®)]] | |||
:* [[Chloroquine|Chloroquine (Aralen®)]] | |||
:* [[Ciprofloxacin|Ciprofloxacin (Cipro®, Cipro-XR®, Neofloxin®)]] | |||
:* [[Clarithromycin|Clarithromycin (Biaxin®, Prevpac®)]] | |||
:* [[Erythromycin|Erythromycin (A/T/S®, Akne-Mycin®, Emgel®, Ery-Tab®, Eryc®, Erycette®, Eryderm®, Erygel®)]] | |||
:* [[Fluconazole|Fluconazole (Diflucan®, Trican®)]] | |||
:* [[Halofantrine|Halofantrine (Halfan®)]] | |||
:* [[Levofloxacin|Levofloxacin (Levaquin®, Tavanic®)]] | |||
:* [[Moxifloxacin|Moxifloxacin (Avelox®, Avalox®, Avelon®)]] | |||
:* [[Pentamidine|Pentamidine (Pentam®)]] | |||
:* [[Sparfloxacin|Sparfloxacin (Zagam®)]] | |||
* '''Drugs with possible TdP risk''' | |||
::* [[ | :* [[Atazanavir|Atazanavir (Reyataz®)]] | ||
::* [[ | :* [[Bedaquiline|Bedaquiline (Sirturo®)]] | ||
:* [[Dihydroartemisinin-Piperaquine|Dihydroartemisinin-Piperaquine (Eurartesim®)]] | |||
:* [[Foscarnet|Foscarnet (Foscavir®)]] | |||
:* [[Gatifloxacin|Gatifloxacin (Tequin®)]] | |||
:* [[Gemifloxacin|Gemifloxacin (Factive®)]] | |||
:* [[Norfloxacin|Norfloxacin (Noroxin®, Ambigram®)]] | |||
:* [[Ofloxacin|Ofloxacin (Floxin®)]] | |||
:* [[Rilpivirine|Rilpivirine (Edurant®, Complera®, Eviplera®)]] | |||
:* [[Roxithromycin|Roxithromycin (Rulide®, Xthrocin®, Roxl-150®, Roxo®, Surlid®, Rulide®, Biaxsig®, Roxar®, Roximycinv®, Roxomycin®, Rulid®, Tirabicin®, Coroxin®)]] | |||
:* [[Saquinavir|Saquinavir (Invirase®(combo))]] | |||
:* [[Telavancin|Telavancin (Vibativ®)]] | |||
:* [[Telithromycin|Telithromycin (Ketek®)]] | |||
* '''Drugs with conditional TdP risk''' | |||
::* [[ | :* [[Amantadine|Amantadine (Symmetrel®, Symadine®)]] | ||
:* [[Hydroxychloroquine|Hydroxychloroquine (Plaquenil®, Quineprox®)]] | |||
:* [[Itraconazole|Itraconazole (Sporanox®, Onmel®)]] | |||
:* [[Ketoconazole|Ketoconazole (Nizoral®, Sebizole®, Ketomed®, Keton®)]] | |||
:* [[Metronidazole|Metronidazole (Flagyl® and many others)]] | |||
:* [[Nelfinavir|Nelfinavir (Viracept®)]] | |||
:* [[Posaconazole|Posaconazole (Noxafil®, Posamol®)]] | |||
:* [[Quinine sulfate|Quinine sulfate (Qualaquin®)]] | |||
:* [[Ritonavir|Ritonavir (Norvir®)]] | |||
:* [[Telaprevir|Telaprevir (Incivek®, Incivo®)]] | |||
:* [[Voriconazole|Voriconazole (VFend®)]] | |||
* '''Drugs to be avoided by congenital Long QT''' | |||
:* [[Trimethoprim-Sulfamethoxazole|Trimethoprim-Sulfamethoxazole (Septra®, Bactrim®, Sulfatrim®, Biseptol®, Co-trimoxazole®, Cotrim®, Septrin®, Trisul®)]] | |||
===Torsades de pointes risk stratification schedules for antimicrobial agents {{ID-returntotop}}=== | |||
* '''Schedule I (Highest TdP risk, potent IKr blockers, TdP risk >1%)''' | |||
:* Not available | |||
* '''Schedule II (Significant risk for TdP, particularly when coadministered with CYP inhibitors, relatively potent IKr blockade)''' | |||
:* Not available | |||
* '''Schedule III (Risk for TdP is described, IKr blockade, particularly when coadministered with CYP inhibitors)''' | |||
:* [[Clarithromycin|Clarithromycin (Biaxin®, Prevpac®)]] | |||
:* [[Erythromycin|Erythromycin (A/T/S®, Akne-Mycin®, Emgel®, Ery-Tab®, Eryc®, Erycette®, Eryderm®, Erygel®)]] | |||
:* [[Itraconazole|Itraconazole (Sporanox®, Onmel®)]] | |||
:* [[Ketoconazole|Ketoconazole (Nizoral®, Sebizole®, Ketomed®, Keton®)]] | |||
:* [[Pentamidine|Pentamidine (Pentam®)]] | |||
:* [[Sparfloxacin|Sparfloxacin (Zagam®)]] | |||
:* '''Schedule V (Questionable or minimal risk for QT interval prolongation or TdP)''' | * '''Schedule IV (Minimal risk for TdP, case reports of TdP, mild IKr blockade, may have CYP interactions)''' | ||
:* [[Fluconazole|Fluconazole (Diflucan®, Trican®)]] | |||
:* [[Gatifloxacin|Gatifloxacin (Tequin®)]] | |||
:* [[Gemifloxacin|Gemifloxacin (Factive®)]] | |||
:* [[Levofloxacin|Levofloxacin (Levaquin®, Tavanic®)]] | |||
:* [[Moxifloxacin|Moxifloxacin (Avelox®, Avalox®, Avelon®)]] | |||
:* [[Telithromycin|Telithromycin (Ketek®)]] | |||
:* [[Voriconazole|Voriconazole (VFend®)]] | |||
* '''Schedule V (Questionable or minimal risk for QT interval prolongation or TdP)''' | |||
:* [[Azithromycin|Azithromycin (Zithromax®, Zmax®)]] | |||
:* [[Ciprofloxacin|Ciprofloxacin (Cipro®, Cipro-XR®, Neofloxin®)]] | |||
:* [[Trimethoprim-Sulfamethoxazole|Trimethoprim-Sulfamethoxazole (Septra®, Bactrim®, Sulfatrim®, Biseptol®, Co-trimoxazole®, Cotrim®, Septrin®, Trisul®)]] |
Revision as of 22:07, 31 May 2015
Risk categories for antimicrobial agents known to have an association with TdP Return to Top
- Drugs with known TdP risk
- Azithromycin (Zithromax®, Zmax®)
- Chloroquine (Aralen®)
- Ciprofloxacin (Cipro®, Cipro-XR®, Neofloxin®)
- Clarithromycin (Biaxin®, Prevpac®)
- Erythromycin (A/T/S®, Akne-Mycin®, Emgel®, Ery-Tab®, Eryc®, Erycette®, Eryderm®, Erygel®)
- Fluconazole (Diflucan®, Trican®)
- Halofantrine (Halfan®)
- Levofloxacin (Levaquin®, Tavanic®)
- Moxifloxacin (Avelox®, Avalox®, Avelon®)
- Pentamidine (Pentam®)
- Sparfloxacin (Zagam®)
- Drugs with possible TdP risk
- Atazanavir (Reyataz®)
- Bedaquiline (Sirturo®)
- Dihydroartemisinin-Piperaquine (Eurartesim®)
- Foscarnet (Foscavir®)
- Gatifloxacin (Tequin®)
- Gemifloxacin (Factive®)
- Norfloxacin (Noroxin®, Ambigram®)
- Ofloxacin (Floxin®)
- Rilpivirine (Edurant®, Complera®, Eviplera®)
- Roxithromycin (Rulide®, Xthrocin®, Roxl-150®, Roxo®, Surlid®, Rulide®, Biaxsig®, Roxar®, Roximycinv®, Roxomycin®, Rulid®, Tirabicin®, Coroxin®)
- Saquinavir (Invirase®(combo))
- Telavancin (Vibativ®)
- Telithromycin (Ketek®)
- Drugs with conditional TdP risk
- Amantadine (Symmetrel®, Symadine®)
- Hydroxychloroquine (Plaquenil®, Quineprox®)
- Itraconazole (Sporanox®, Onmel®)
- Ketoconazole (Nizoral®, Sebizole®, Ketomed®, Keton®)
- Metronidazole (Flagyl® and many others)
- Nelfinavir (Viracept®)
- Posaconazole (Noxafil®, Posamol®)
- Quinine sulfate (Qualaquin®)
- Ritonavir (Norvir®)
- Telaprevir (Incivek®, Incivo®)
- Voriconazole (VFend®)
- Drugs to be avoided by congenital Long QT
Torsades de pointes risk stratification schedules for antimicrobial agents Return to Top
- Schedule I (Highest TdP risk, potent IKr blockers, TdP risk >1%)
- Not available
- Schedule II (Significant risk for TdP, particularly when coadministered with CYP inhibitors, relatively potent IKr blockade)
- Not available
- Schedule III (Risk for TdP is described, IKr blockade, particularly when coadministered with CYP inhibitors)
- Schedule IV (Minimal risk for TdP, case reports of TdP, mild IKr blockade, may have CYP interactions)
- Schedule V (Questionable or minimal risk for QT interval prolongation or TdP)